Collaborations with 23andMe Therapeutics can take many different forms.
23andMe is seeking development and commercialization partnerships with biotech and pharmaceutical companies interested in our immuno-oncology clinical assets.
23andMe’s team of experienced biologists and data scientists is investing in the discovery of novel targets in immunology through leveraging the latest 23andMe human genetic data and functional genomic screens. Pharma and biotech companies interested in novel targets in immunology and inflammation should contact 23andMe business development.
Although our own current concentration is on developing antibody therapies in immuno-oncology and immunology/inflammation areas, our years of building and mining the largest set of recontactable genotypic and phenotypic data in the world have created tremendous potential for partners with other interests. Our data extend far beyond the genomes of our customers to include associated phenotype data as well as integrated datasets from publicly available sources. We also have the ability to collect additional human data by resampling banked customer specimens, collecting biosamples, fielding surveys and employing wearables and other technology in disease cohorts of interest.
Collaborators can access the benefits of 23andMe’s dataset in multiple ways, ranging from subscriptions to data, to collaborations that leverage the expertise of the 23andMe data sciences team, and deeper phenotyping of selected cohorts. In addition, the data can be used to validate a collaborator’s existing targets and select the optimal indications.